Dr. Salma Jabbour’s NCI Research Specialist (Clinician Scientist) Award (R50)

摘要 肿瘤临床试验在设计、管理和监督方面越来越复杂， 继续作为改变癌症患者护理的基石。这些多方面的审判需要大量的 该机构和调查人员的伙伴关系，提供支持和努力，以及多方面的团队， 无缝而有效地进行和执行这些审判。此外，临床试验的传播 及时有效地获得研究结果需要临床试验团队的持续支持， 生物统计学家和合作研究者在时间和精力方面。贾布里勒博士是一位经验丰富的研究专家 医生科学家和临床科学家，具有勤奋和创新的良好记录，以及 目的是设计、实施和完成临床试验。她长期致力于临床试验， 最重要的是，她是新泽西罗格斯癌症研究所的领导者，在指导和支持其他 临床试验者，曾监督人类研究监督委员会（HROC/DSMB），目前 监督科学审查委员会，她在监督临床试验方面发挥着不可或缺的作用， 罗格斯癌症研究所和全国的各种委员会。在国家一级，贾布里勒博士是 罗格斯癌症研究所ETCTN/CTEP赠款资金的PI联系人，是NCI的长期联合主席 放射研究计划胃肠兴趣小组，并积极参与各种NCI 合作小组委员会和协议，包括ECOG-ACRIN和NRG肿瘤学合作 组作为临床医生科学家，Jabbrilliant博士是一位持续的领导者和先驱，并积极研究 在突破性的临床试验中，新的药物与放射联合使用。贾布里勒医生会继续 在这一R50机制的主持下，我们将作出堪称典范的努力和工作，并将继续彻底改变 通过她最先进的概念和通过NCI国家合作来照顾肿瘤患者 合作团体。

ABSTRACT Oncology clinical trials are increasingly complex in their design, management, and oversight, and clinical trials continue as the cornerstone to transform cancer care for patients. These multifaceted trials require significant partnership from the institution and investigators to provide support and effort as well as multifaceted teams to conduct and execute these trials seamlessly and effectively. Furthermore, the dissemination of clinical trial findings in a timely and efficient manner requires the continued support from the clinical trials teams, biostatisticians, and co-investigators in terms of time and effort. Dr. Jabbour is a seasoned research specialist, physician scientist, and clinician scientist having a proven track record of diligence and innovation as well as purpose to design, carry out, and complete clinical trials. Her long-standing commitment to clinical trials is paramount as she is a leader at the Rutgers Cancer Institute of New Jersey in mentoring and supporting other clinical trialists, having overseen the Human Research Oversight Committee (HROC/DSMB) and currently overseeing the Scientific Review Board, and she plays integral role in the oversight of clinical trials through a variety of committees both at Rutgers Cancer Institute and nationally. At the national level, Dr. Jabbour is the contact PI for the Rutgers Cancer Institute ETCTN/CTEP grant funding, is a long-standing Co-Chair for the NCI Radiation Research Program Gastrointestinal Interest Group, and is actively involved in a variety of NCI Cooperative Group Committees and Protocols including the ECOG-ACRIN and NRG Oncology Cooperative Groups. Dr. Jabbour is a continued leader and pioneer as a clinician scientist and actively studies the use of novel agents in combination with radiation in ground-breaking clinical trials. Dr. Jabbour will continue her exemplary efforts and work under the auspices of this R50 Mechanism and will continue to revolutionize the care for oncology patients through her state-of-the-art concepts and collaborations through the NCI national cooperative groups.